// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Chemotherapy related tumour lysis syndrome in patients with haematological cancer and pre‐existing renal impairment – a Large District General Hospital Experience

S Hebballi - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bendamustine

Patient and physician perceived disconnects in the communication and disease management of myeloproliferative neoplasms

C Harrison - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A rare case of blood cytopenias in a middle aged adult due to use of a dental product

E Maragkoudakis - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Review of outpatient clinical practice of haematology consultants across south Wales: follow‐up intervals and discharges

L Morgan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Diagnosis and management of warm autoimmune haemolysis – a review of five years experience in this rare condition at the Royal Cornwall Hospital

S Johns - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

An analysis of the cost savings achieved through the practice of vial sharing for patients on romiplostim (NPLATE®) treatment in a district general hospital haematology unit over a six month period

S Kundu - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Romiplostim

A retrospective analysis of GP referrals made under the 2 week wait pathway for suspected haematological cancers

S Mackenzie - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Are we managing polycythaemia vera patients optimally? A single centre audit

R Katmeh - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Hydroxycarbamide

Secondary erythrocytosis: evaluation of the current practice of a large teaching hospital

AKAAM Asa'ari - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cytomegalovirus: an interesting case of ITP

K Leighton - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

TA-9070

T cells in the bone marrow – the real drivers of immune thrombocytopaenia?

T Mayo - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Two years following real life implementation of a ‘matching michigan’ approach: are we continuing to minimise central venous line infection rates?

J Young - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

ZoMaxx

Do haematologists in England engage with social media?

N Borges - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The investigation and outcome of patients referred with symptoms alone on the two‐week‐wait pathway

F Emond - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

The safety profile of Hickman and peripherally inserted (PICC) central venous catheters in patients receiving intensive chemotherapy with haematological malignancies – a one year retrospective study

V Dhanapal - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

vancomycin capsule

Interim analysis of the TARGET UK study: real‐world use of tyrosine kinase inhibitors in UK patients with chronic myeloid leukaemia

D Milojkovic - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nilotinib

Characterisation of innate immune responses to viral infection in patients following allogeneic haematopoietic stem cell transplantation

S Caddy - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon alpha

Intravenous and oral dosing of ciclosporin in allogeneic stem cell transplantation

H Lam - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Cyclosporine A

Mobilising PBSC for autologous transplantation: comparing cyclophosphamide 1.5 g/m2 against 750 mg/m2

A Gibson - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

Pegylated filgrastim compared to filgrastim for stem cell mobilization in multiple myeloma

MB Abid - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

Copyright © 2026. QuantiNova All rights reserved